Curadel Surgical Innovations (CSI) Moves Flagship Contrast Agent for Image-guided Surgery, ZW800-1, Towards Commercialization
ZW800-1 is a first-in-class near-infrared fluorescent (NIR) contrast agents called zwitterionic. The investigational contrast agent, when used in conjunction with an appropriate imaging system, provides contrast by converting NIR light from a lower wavelength to a higher one, visually enhancing the anatomical structure with high sensitivity and specificity. With high brightness and renal-only clearance, a low dose of ZW800-1 has been shown in Phase 2 clinical trials to provide several hours of visualization of the ureters. Currently, intraoperative identification of the ureters during abdominal and pelvic surgeries is extremely difficult.
The company is developing additional contrast agents using the FLARE® technology platform to enhance the anatomy of malignant and non-malignant tumors, blood vessels, nerves, lymph nodes, intervertebral discs, and cartilage.
“Near-infrared fluorescent light empowers surgeons to see anatomy that would otherwise be invisible, in real-time,” said John V. Frangioni, M.D., Ph.D., Chief Executive Office of Curadel Surgical Innovations. “ZW800-1 is only the beginning of what FLARE® can do for the surgical community.”
FLARE® Technology was invented by Dr. Frangioni while he was a professor of medicine and radiology at the Harvard Medical School. The technology is owned by Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, and is licensed to CSI.
About Curadel Surgical Innovations, Inc.
Founded in 2014, Curadel Surgical Innovations, Inc. (CSI) is a privately held company headquartered in Natick, Mass. specializing in the development, manufacture, marketing, and commercialization of contrast agents for image-guided surgery.
To learn more about Curadel Surgical Innovations, Inc., and its pipeline, please visit www.curadelsurgicalinnovations.com.
Source: Curadel Surgical Innovations Inc.